Učitavanje...
Hepatic toxicity during regorafenib treatment in patients with metastatic gastrointestinal stromal tumors
Regorafenib is a multi-target tyrosine kinase inhibitor that has been approved for the treatment of metastatic colorectal cancer, advanced hepatocellular carcinoma, and metastatic gastrointestinal stromal tumors (GIST). Severe hepatobiliary toxicity has been reported in patients with colorectal canc...
Spremljeno u:
| Izdano u: | Mol Clin Oncol |
|---|---|
| Glavni autori: | , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
D.A. Spandidos
2020
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7523284/ https://ncbi.nlm.nih.gov/pubmed/33005406 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2020.2143 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|